Ranibizumab v léčbě věkem podmíněné makulární degenerace
| Title in English | Ranibizumab in treatment of age-related macular degeneration |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | ORL, ophthalmology, stomatology |
| Keywords | ranibizumab; treatment; wet form of age-related macular degeneration; diabetic macular oedema; retinal vein occlusion |
| Description | Ranibizumab is a fragment of a recombinant humanized monoclonal antibody against vascular endothelial growth factor. Its action results in reduced proliferation of endothelial cells, reduced vascular permeability, and it stops the formation of new vessels. Ranibizumab is indicated for intravitreal treatment of wet age-related macular degeneration, in the treatment of diabetic macular oedema, and macular edema (ME) caused by retinal vein occlusion for the treatment of choroidal neovascularization (CNV) secondary to pathological myopia (PM). |